Remove 2024 Remove Community Remove Medical Specialty Remove Provider
article thumbnail

At Long Last, FDA Unveils Plan for Rare Disease Innovation Hub

FDA Law Blog

Importantly, the Hub is intended to establish a new model within FDA, which leverages cross-Agency expertise in providing guidance and conducting reviews for products for rare disease populations. those reviewed by the CDER Division of Rare Diseases and Medical Genetics). By Sarah Wicks & James E. Valentine & Frank J.

article thumbnail

Endocrinology, Diabetes and Metabolism Board Meeting Summary | Spring 2025

ABIM

Expanding ABIM’s engagement with stakeholder communities such as early career physicians, specialty societies and patient-focused organizations. In 2024, 77% of eligible ABIM Board Certified endocrinologists who chose an assessment opted for the LKA over the traditional, 10-year MOC exam.

article thumbnail

Infectious Disease Board Meeting Summary | Spring 2025

ABIM

JD , whose terms on the Specialty Board end June 30, 2025. Expanding ABIM’s engagement with stakeholder communities such as early career physicians, specialty societies and patient-focused organizations. This is now being reviewed by the American Board of Medical Specialties, which oversees ABIM.